Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer Oct. 31, 2024 — A new study has found a surprising link between high levels of methylmalonic acid and the weakening of ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Edgardo S. Santos, MD, FACP, FASCO, a hematologist and medical oncologist, discussed how artificial intelligence (AI) is revolutionizing lung cancer care by analyzing imaging data to detect ...

Lung cancer disproportionately affects Black communities. Discover the causes, risk factors, and prevention strategies to ...

HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...

POSTECH & Kyungpook National University develop inhalable lung cancer therapeutics utilizing mucoadhesive proteinic ...

Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...

The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...